We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


WuXi PharmaTech Laboratory Testing Division Expands in U.S.

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "WuXi PharmaTech Laboratory Testing Division Expands in U.S."

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

WuXi PharmaTech(Cayman) Inc. (WuXi) has announced that it has acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of successful operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries.

Financial terms were not disclosed. The transaction closed on September 30, 2014, and is expected to be neutral to WuXi’s 2014 diluted EPS and accretive to WuXi’s 2015 diluted EPS on a non-GAAP basis.

The acquisition bolsters WuXi’s Laboratory Testing Division (LTD) in bioanalytical and DMPK/ADME services, particularly in studies of radio-labeled compounds, while gaining access to new agricultural and animal health customers. The resulting expansion and enhancement of WuXi’s integrated service portfolio will accelerate the growth of LTD’s business and further strengthen WuXi’s position as a leading research and development service provider to the pharmaceutical and biotech industries.

This acquisition expands LTD’s presence in North America, provides greater flexibility in service and support options for our North American customers, and presents the opportunity for further expansion.

XBL has 150 employees and operates a 45,000-square-foot research center in Plainsboro, New Jersey, and a 36,000-square-foot facility in Nanjing, China. The company is FDA- and USDA-registered, New Jersey-licensed for work with radioisotopes, USDEA-licensed for conducting research with Schedule 1-5 controlled substances, and AAALAC-accredited.

“My colleagues and I are very excited to join WuXi, a global leader in providing drug discovery and development services to the global biopharmaceutical industry,” said Dr. Jinn Wu, President and Chief Executive Officer of XBL, who has been appointed Vice President and Chief Scientific Officer of LTD. “We will continue to provide our services to our current clients while also offering expanded services to WuXi’s clients.”

“We are very pleased to have XBL join the WuXi team,” said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi. “Dr. Wu has spent the past 27 years building a solid organization and reputation within the industry. This business combination is an important step in WuXi’s development of a comprehensive, integrated platform of R&D services to help our customers discover and develop drugs more efficiently and cost-effectively.”